Experimental combo aims to overcome drug resistance in metastatic cancers
NCT ID NCT04150042
First seen Jan 30, 2026 · Last updated Jun 22, 2026 · Updated 22 times
Summary
This early-stage trial is testing a combination of two chemotherapy drugs (melphalan and BCNU) plus vitamins B12b and C, followed by an infusion of the patient's own stem cells. The goal is to see if this approach is safe for people with metastatic pancreatic or breast cancer, especially those with BRCA or PALB2 mutations. The study involves 24 participants and uses a dose-escalation plan for vitamin C to find the safest dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
COMPLETEDBoston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Melphalan, BCNU (carmustine), vitamin B12b (hydroxocobalamin), vitamin C (ascorbic acid), and autologous hematopoietic stem cells
What this could lead to
If this trial shows safety, it could point toward a new treatment option for people with metastatic pancreatic or breast cancer who have specific genetic mutations.
What could go wrong
This is a very early phase 1 trial with only 24 participants, focused on safety, not effectiveness. The treatment involves strong chemotherapy with serious risks like liver damage, lung problems, and kidney injury.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.